<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">
home-lungs

2021 ASCO Annual Meeting

 

We are excited to be exhibiting at #ASCO21. Visit our virtual booth to learn more.

VISIT BOOTH

NEWS

BEACON-Lung Progress

First patient enrolled in Biodesix and Addario Lung Cancer Medical Institute Study aiming to predict patient survival using a blood-based biomarker.

VIEW PRESS RELEASE

VIEW POSTER

COMING SOON!

Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time.

Read More 

nodifylung-654

Nodify Lung™ testing consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2® tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.

 

Learn More

Biodesix Lung Color Logo

Biodesix Lung Reflex® testing consists of the GeneStrat® tumor profiling test and the VeriStrat® immune profiling test to provide physicians with timely molecular results to facilitate treatment decisions for patients with non-small cell lung cancer.

 

Learn More
biopharma-services

We provide biopharmaceutical companies with end-to-end diagnostic services inclusive of diagnostic research and feasibility, assay development, clinical trial testing, and commercialization of companion diagnostics.

 

Learn More

Recent Presentations

Real-World Performance of Blood-Based Host Immune Profiling in First-line Immunotherapy Treatment

Presented by: Wallace Akerley, MD
Huntsman Cancer Institute
Chairman, Protocol Review & Monitoring Committee: Director, Lung Cancer Disease Center of Excellence, Medical Oncologist

Watch Now

AI Coupled with Mass Spectrometry for Immunotherapy Diagnostic Test Development

Presenter: Robert Georgantas III, Ph.D.
SVP, Research and Translational Science
Biodesix

Recorded at IO 360 on February 25, 2021

Watch Now

Contact us with any questions

REACH OUT TO OUR TEAM